GENE ONLINE|News &
Opinion
Blog

ADCs
Sanofi Bets $2.5 billion on Adagene to Make Antibodies Safer
2022-03-03
Astellas, Seagen Cancer Drug Becomes First and Only Approved ADC For Advanced Urothelial Cancer in Japan
2021-09-28
Seagen, Genmab’s Antibody Drug Conjugate Bags FDA Approval for Cervical Cancer
2021-09-22
Seagen Licenses ADC Asset From a Chinese Player to Disrupt HER2 Market
2021-08-10
Roche Aspires for Dominance in DLBCL Market, Unveils Pivotal Trial Data for Polivy
2021-08-09
Sparx Therapeutics to Build a Massive Manufacturing Plant in China for Multi-Specific Antibody Production
2021-07-10
BMS Initiates Global Partnership to Advance Eisai’s First ADC to Market
2021-06-20
WuXi Biologics and WuXi STA Establish Joint Venture to Advance Bioconjugates
2021-05-17
Antibody Drug Conjugates: The Next Big Thing in Cancer Therapy?
2021-03-20
Astellas Submits New Drug Application Targeting First ADC Approval for Metastatic Urothelial Cancer in Japan
2021-03-13
Boehringer Ingelheim’s Newest Acquisition Reinforces its Focus on Immuno-Oncology
2020-12-14
ASH2020: VelosBio’s ROR1 Targeted Therapy Shines in Safety Trial
2020-12-09
Hot Pursuit for Antibody Drug Conjugates Continue as Merck Acquires VelosBio
2020-11-06
IPO
Drawing Millions in Investment, RemeGen is Ready to Bag 514m in IPO
2020-10-29
Investors Back Seattle-Based Startup’s Novel Immuno-Oncology Program Targeting Solid Tumors
2020-09-26
1 2
LATEST
Pfizer’s RSV Vaccine Gets FDA Approval for Use in Older Adults
2023-05-31
Brazil’s Evolving ESG Landscape from the Amazon to Atlantic Forest
2023-05-31
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
Scroll to Top